Altamira Therapeutics Ltd. (NASDAQ:CYTO) Short Interest Up 12.8% in August

Altamira Therapeutics Ltd. (NASDAQ:CYTO) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 180,200 shares, an increase of 12.8% from the August 15th total of 159,800 shares. Approximately 8.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 438,800 shares, the days-to-cover ratio is currently 0.4 days.

Altamira Therapeutics Stock Performance

Shares of CYTO traded down $0.09 during trading hours on Monday, hitting $0.75. 111,783 shares of the company were exchanged, compared to its average volume of 914,766. The firm has a fifty day simple moving average of $1.04 and a 200-day simple moving average of $1.41. Altamira Therapeutics has a one year low of $0.73 and a one year high of $17.20.

About Altamira Therapeutics

Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.